Mangoceuticals Inc (MGRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown a significant increase in sales for its TRT program, the financial performance remains weak, with declining revenue and negative EPS. Additionally, there are no strong technical or proprietary trading signals supporting an immediate purchase. It is better to monitor the stock for further developments or improvements in financial performance before considering a buy.

Technical Analysis

The MACD histogram is positive at 0.0364 but contracting, indicating weakening momentum. RSI is neutral at 67.06, and moving averages are converging, showing no clear trend. Key support is at 0.367, and resistance is at 0.626. The pre-market price of 0.495 is near the pivot level of 0.496, suggesting indecision in the market.

Positive Catalysts

The company's injectable testosterone replacement therapy (TRT) sales increased by 336% month-over-month, and customer acquisition costs dropped by 54%. This has led to a significant short-term rise in stock price.

Neutral/Negative Catalysts

The company's financials for 2025/Q3 show a 36.83% drop in revenue YoY, a negative EPS of -0.69, and a gross margin decline of 2.53%. The pre-market price is down 4.62%, indicating negative sentiment.

Financial Performance

In 2025/Q3, revenue dropped by 36.83% YoY to 84,246. Net income improved but remains negative at -7,912,218, up 295.76% YoY. EPS dropped significantly to -0.69, down 95.35% YoY. Gross margin decreased slightly to 60.42%, down 2.53% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast MGRX stock price to rise

Buy

Hold

Sell

Current: 0.535

Low

Averages

High